Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan-Dec:26:1076029620962853.
doi: 10.1177/1076029620962853.

COVID-19 and Hypercoagulability: A Review

Asim Kichloo  1   2 , Kirk Dettloff  2 , Michael Aljadah  3 , Michael Albosta  2 , Shakeel Jamal  1   2 , Jagmeet Singh  4 , Farah Wani  5 , Akshay Kumar  6 , Srilakshmi Vallabhaneni  7 , Muhammad Zia Khan  8
Affiliations
Review

COVID-19 and Hypercoagulability: A Review

Asim Kichloo et al. Clin Appl Thromb Hemost. 2020 Jan-Dec.

Abstract

Thrombotic complications of the novel coronavirus (COVID-19) are a concerning aspect of the disease, due to the high incidence in critically ill patients and poor clinical outcomes. COVID-19 predisposes patients to a hypercoagulable state, however, the pathophysiology behind the thrombotic complications seen in this disease is not well understood. Several mechanisms have been proposed and the pathogenesis likely involves a host immune response contributing to vascular endothelial cell injury, inflammation, activation of the coagulation cascade via tissue factor expression, and shutdown of fibrinolysis. Treatments targeting these pathways may need to be considered to improve clinical outcomes and decrease overall mortality due to thrombotic complications. In this review, we will discuss the proposed pathophysiologic mechanisms for thrombotic complications in COVID-19, as well as treatment strategies for these complications based on the current literature available.

Keywords: coagulopathy; embolism; venous thromboembolism.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Proposed mechanisms of thrombosis in COVID-19 diagnosed patients.
See this image and copyright information in PMC

References

    1. Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382(13):1199–1207. - PMC - PubMed
    1. WHO. Modes of transmission of virus causing COVID-19: implications for IPC precaution recommendations. World Health Organization. 2020. Accessed October 8, 2020 https://www.who.int/news-room/commentaries/detail/modes-of-transmission-...
    1. WHO. WHO coronavirus disease (COVID-19) dashboard. World Health Organization. 2020. Accessed October 8, 2020 https://covid19.who.int/
    1. Klok FA, Kruip MJHA, Van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145–147. - PMC - PubMed
    1. Tang N, Li D, Wang X, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844–847. - PMC - PubMed

LinkOut - more resources